Liminatus Pharma, Inc. Warrants(LIMNW)Earnings, Financials & Key Ratios
LIMNW•NASDAQ
$0.04
Price updated Jun 27, 2026
AboutLiminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.Show more
- Revenue$0
- EBITDA-$3M-8.0%
- Net Income-$10M-251.4%
- EPS (Diluted)-0.43-7.5%
LIMNW Price & Volume
Liminatus Pharma, Inc. Warrants (LIMNW) stock price & volume — 10-year historical chart
Loading chart...
Liminatus Pharma Faces Imminent Terminal Liquidity Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk
Key Thesis Takeaways
- Liminatus Pharma operates as a pre-revenue biotechnology entity with no commercial product sales, leaving it entirely dependent on external capital to fund its GUCY2C-targeted CAR-T development.
- The company's financial position has deteriorated significantly, characterized by a persistent negative equity balance of -$9.8 million as of 2025Q4 and a lack of disciplined cost management.
- Investors should exercise extreme caution as the firm's dwindling cash reserves and recurring operational losses suggest a high probability of a terminal liquidity event.
Verdict Logic
the company's cash reserves of $337,655 are insufficient to sustain its high-cost CAR-T clinical trial pipeline, indicating a critical risk of insolvency.
LIMNW Growth Metrics
Liminatus Pharma, Inc. Warrants (LIMNW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-437.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM85.54%
Return on Capital
10 Years-16.28%
5 Years-16.28%
3 Years-46.02%
Last Year-
Peers Comparison
Key metrics vs top competitors for Liminatus Pharma, Inc. Warrants (LIMNW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.04 | $955.27K | -0.08 | — | — | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $10.99 | $351.66M | 4.78 | 6774.96% | -256.6% | -17.04% | — | |
| $182.08 | $38.71B | -30.60 | — | — | -83.22% | — |
Compare LIMNW vs Peers
Liminatus Pharma, Inc. Warrants (LIMNW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when LIMNW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LIMNW Frequently Asked Questions
Liminatus Pharma, Inc. Warrants (LIMNW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is LIMNW profitable?
Liminatus Pharma, Inc. Warrants (LIMNW) reported a net loss of $11.0M for fiscal year 2025.
Dividend & Returns
What is Liminatus Pharma, Inc. Warrants's free cash flow?
Liminatus Pharma, Inc. Warrants (LIMNW) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.